Patents by Inventor Jonas Andrej NILSSON

Jonas Andrej NILSSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DELIVERY OF THERAPEUTIC AGENT
    Publication number: 20200063138
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 27, 2020
    Applicant: Codiak BioSciences, Inc.
    Inventors: Jan LÖTVALL, Jonas Andrej NILSSON
  • Delivery of therapeutic agent
    Patent number: 10370663
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 6, 2019
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Jonas Andrej Nilsson
  • DELIVERY OF THERAPEUTIC AGENT
    Publication number: 20180135056
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 17, 2018
    Inventors: Jan LÖTVALL, Jonas Andrej NILSSON
  • Delivery of therapeutic agent
    Patent number: 9856477
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: January 2, 2018
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Jonas Andrej Nilsson
  • DELIVERY OF THERAPEUTIC AGENT
    Publication number: 20160168572
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Application
    Filed: November 13, 2013
    Publication date: June 16, 2016
    Inventors: Jan LÖTVALL, Jonas Andrej NILSSON